Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes

• US 6,207,170 B1
• Filed: 01/15/1999
• Issued: 03/27/2001
• Est. Priority Date: 01/16/1998
• Status: Expired due to Fees

• Current Assignee: Oncothyreon Incorporated (Pfizer Inc.)
• Original Assignee: Biomira U.S.A., Inc. (Pfizer Inc.)
• Inventors: Boni, Lawrence, Popescu, Mircea C., Robb, Richard J., Batenjany, Michael M.
• Primary Examiner(s): Huff, Sheela
• Assistant Examiner(s): DENT, ALANA HARRIS
• Application Number:
  US09/231,650
• Time in Patent Office: 802 Days
• Field of Search: 424/1.11, 424/1.21, 424/1.29, 424/1.41, 424/1.57, 424/1.69, 424/1.73, 424/184.1, 424/277.1
• US Class Current: 424/277.1
• CPC Class Codes: A61K 2039/55522 Cytokines; Lymphokines; Interferons
• CPC Class Codes: A61K 2039/55527 Interleukins
• CPC Class Codes: A61K 2039/55533 IL-2
• CPC Class Codes: A61K 2039/5555 Muramyl dipeptides
• CPC Class Codes: A61K 2039/55572 Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia

Abstract

Membrane-proteoliposome structures (MPs) are useful in preparing patient-specific vaccines against specific white blood cell (WBC) malignancies. The inventive MPs typically contain a membrane component derived from a specific WBC. Other useful components include immunostimulators and exogenous lipids. The resulting vaccines are both patient- and malignancy-specific.

Claims

1. A patient-specific vaccine for treating white blood cell malignancy, comprising a membrane-proteoliposome (MP) containing plasma membrane from a malignant white blood cell.

2. A vaccine according to claim 1, wherein said malignant white blood cell is a lymphoma cell.

3. A vaccine according to claim 1, wherein said malignant white blood cell is a leukemia cell.

4. A vaccine according to claim 1, wherein said malignant white blood cell is a myeloma cell.

5. A membrane-proteoliposome (MP), comprising integral membrane from a malignant white blood cell, at least one immunostimulator and an exogenous lipid.

6. An MP according to claim 5, wherein said membrane contains at least one membrane component involved in immunity.

7. An MP according to claim 5, comprising at least two immunostimulators.

8. An MP according to claim 6, wherein said component is selected from the group consisting of a tumor-specific antigen, a major histocompatability complex antigen and a costinulatory molecule.

9. An MP according to claim 8, wherein said costimulatory molecule is CD80 or CD86 or ICAM-1.

10. An MP according to claim 5, wherein said immunostimulator is a lymphokine.

11. An MP according to claim 10, wherein said lymphokine is IL-2.

12. An MP according to claim 5, wherein said immunostimulator is an interferon.

13. An MP according to claim 12, wherein said interferon is IFN-γ

.

14. An MP according to claim 5, wherein said immunostimulator is a cytokine.

15. An MP according to claim 14, wherein said cytokine is GM-CSF or M-CSF.

16. An MP according to claim 5, wherein said immunostimulator is an adjuvant.

17. An MP according to claim 16, wherein said adjuvant is selected from the group consisting of monophosphoryl lipid A, lipid A and muramyl dipeptide (MDP) lipid conjugate.

18. An MP according to claim 5, wherein said lipid is a saturated or unsaturated phospholipid or a glycolipid.

19. A MP according to claim 18, wherein said lipid is selected from the group consisting of 1,2-dimyristoylphosphatidylcholine, 1,2-dipalmitoylphosphatidylcholine, 1,2-dimyristoylphosphatidylglycerol, cholesterol and combinations thereof.

20. An MP according to claim 5, wherein said lipid forms a membrane within which said integral membrane is patched.

21. An MP according to claim 5, wherein said lipid forms patches within said integral membrane.